Suppr超能文献

[睾丸肿瘤患者的BEP化疗——是否值得?]

[BEP-chemotherapy in patients with testicular tumors--is it worthwhile?].

作者信息

Hess U, Jungi W F, Morant R, Schmid L, Senn H J, Bandhauer K

机构信息

Medizinische Klinik C, Kantonsspital St. Gallen.

出版信息

Schweiz Med Wochenschr. 1990 Dec 8;120(49):1883-6.

PMID:1702233
Abstract

Since 1985 44 consecutive patients with testicular cancer have been treated with a modified BEP regimen. 70% had metastatic disease and 30% received adjuvant therapy. After mean follow-up of 26 (8-56) months, 91% of patients are alive and all are in remission. Chemotherapy-related side effects were alopecia (100%), myelosuppression (100%), nausea/vomiting (89%) and fever (66%). Patients reported nausea has been rare. It is concluded that BEP chemotherapy is a highly effective treatment which secures complete remission or cure even in patients with advanced metastatic disease. In retrospect the patients considered the treatment worthwhile despite the stress involved.

摘要

自1985年以来,44例连续的睾丸癌患者接受了改良的BEP方案治疗。70%的患者患有转移性疾病,30%接受了辅助治疗。平均随访26(8 - 56)个月后,91%的患者存活且均处于缓解状态。化疗相关的副作用包括脱发(100%)、骨髓抑制(100%)、恶心/呕吐(89%)和发热(66%)。报告恶心的患者很少见。结论是,BEP化疗是一种高效的治疗方法,即使对于晚期转移性疾病患者也能确保完全缓解或治愈。回顾来看,尽管治疗过程有压力,但患者认为这种治疗是值得的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验